The proposed public offering of common stock by Iovance Biotherapeutics could lead to dilution of existing shareholders' equity. This could potentially lead to a decrease in the stock price in the short term as the market adjusts to the increased number of shares. However, the proceeds from the offering could strengthen the company's financial position in the long term.